Michael Wang, MD

Treatment with mosunetuzumab and polatuzumab vedotin led to a complete response rate of 79% in patients with mantle cell lymphoma.

Mosunetuzumab plus polatuzumab vedotin demonstrated efficacy in subgroups of patients with mantle cell lymphoma with poor risk factors.

The mosunetuzumab and polatuzumab vedotin combination was evaluated in a high-risk factor subgroup of patients with mantle cell lymphoma.

Michael Wang, MD, gives an overview of the progress that has been made in mantle cell lymphoma research and where research should be focused on new treatment strategies and improved understanding of the disease.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Michael Wang, MD, spoke about key data from the phase 3 SHINE trial which analyzed the use of first-line ibrutinib plus bendamustine and rituximab in older patients with mantle cell lymphoma.

This article presents an overview of the cardiac and pulmonary safety profile of single-agent carfilzomib therapy in patients with relapsed and/or refractory multiple myeloma from an analysis of four phase II clinical studies, and provides practical recommendations for the management of patients at risk for cardiac events and pulmonary complication.

The proteasome is an important therapeutic target in the treatment of a small but increasing number of diseases- most notably, B cell malignancies. Multiple myeloma (MM) is one of the first diseases for which proteasome inhibitors (PIs) have been validated and in which they have found widespread use.